Comparative Pharmacology
Head-to-head clinical analysis: FOCINVEZ versus GRISACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOCINVEZ versus GRISACTIN.
FOCINVEZ vs GRISACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FOCINVEZ is a small-molecule inhibitor of the interaction between the N-terminal domain of the androgen receptor (AR) and the AR N-terminal domain coactivator binding site, thereby blocking AR-mediated gene transcription and inhibiting prostate cancer cell growth.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
Intravenous: 1.5 mg/kg every 6 hours; maximum single dose: 200 mg.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours; allows twice-daily dosing in most patients, extended in renal impairment (up to 30-40 hours in severe impairment).
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
Renal: 70% (unchanged drug), Biliary/Fecal: 20% (metabolites), Other: 10% (minor pathways).
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Category C
Category C
Antifungal
Antifungal